Lipid Conjugate Technology Platform

Chimerix’s innovative lipid conjugate technology addresses two common issues:
  1. Avoiding some unwanted side-effects of medicines currently available
  2. Addressing poor absorption of oral medication through the attachment of lipid side-chains to antivirals, such as nucleotides. These lipid–antiviral conjugates are thought to facilitate absorption of the compound across the gut, into the bloodstream, and deliver it in higher concentrations to targeted cells where viral replication occurs.
Chimerix is currently developing its lipid-nucleotide conjugate brincidofovir (CMX001).


In 2011, Chimerix received a grant of $81 million from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to continue exploring the development of brincidofovir (CMX001) as a medical countermeasure to treat potential smallpox outbreaks in the event of a bioterror attack or accidental release.

The Chimerix smallpox animal efficacy development program is being conducted under the U.S. Food and Drug Administration’s Animal Efficacy Rule, which allows for testing of investigational drugs in animal models to support effectiveness in diseases that are not ethical or feasible to study in humans. Results from studies of brincidofovir in both rabbit and mouse models of smallpox showed improved survival when compared to placebo, even when treatment was initiated late in the course of disease.

If successful, brincidofovir could be an important contribution to the U.S. national security and public health preparedness for the treatment of smallpox.